CD47 and hepatocellular carcinoma: These patients may benefit from novel MET targeting strategies already available in clinical trials for hepatocellular carcinoma and non-small cell lung carcinoma, as well as from future CD47/SIRPalpha targeting strategies that have proven efficacy in pre-clinical trials.